Table 1 Patient characteristics
Variables | Newly diagnosed (n = 12) | After PCD treatment (n = 12) | P |
|---|---|---|---|
Median age, years (range) | 59 (39–74) | ||
Sex (M/F) | 4/8 | ||
Durie-Salmon staging, n (%) | |||
Stage IA | – | 3 (25%) | |
Stage IIA | 1 (8.33%) | – | |
Stage IIB | – | – | |
Stage IIIA | 9 (75%) | 8 (66.67%) | |
Stage IIIB | 2 (16.67%) | 1 (8.33%) | |
ISS, n (%) | |||
Stage I | – | – | |
Stage II | 7 (58.33%) | 12 (100%) | |
Stage III | 5 (41.67%) | – | |
Median glb (g/L), (range) | 42.65 (17.4–89.8) | 22.05 (15.7–42.4) | 0.015 |
≥35 g/L | 6 (50%) | 1 (8.33%) | |
<35 g/L | 6 (50%) | 11 (91.67%) | |
Median β2-microglobulin (mg/L), (range) | 5.14 (2.66–22.4) | 2.355 (1.74–3.8) | 0.012 |
≥5.5 mg/L | 6 (50%) | – | |
<5.5 mg/L | 6 (50%) | 12 (100%) | |
Median Hb (g/L), (range) | 107 (67–140) | 124 (100–137) | 0.059 |
≥105 g/L | 7 (58.33%) | 11 (91.67%) | |
<105 g/L | 5 (41.67%) | 1 (8.33%) | |
Median Cre (μmol/L), (range) | 61.5 (55–400) | 58.5 (36–166) | 0.199 |
≥104 μmol/L | 3 (25%) | 1 (8.33%) | |
<104 μmol/L | 9 (75%) | 11 (91.67%) | |
Median Ca ++ (mmol/L) (range) | 2.305 (1.95–4.19) | 2.145 (1.87–2.28) | 0.087 |
≥2.54 mmol/L | 3 (25%) | – | |
<2.54 mmol/L | 9 (75%) | 12 (100%) | |
LDH(U/L) (range) | 170 (145–300) | 202 (173–266) | 0.342 |
Normal | 10 (83.33) | 9 (75%) | |
High | 2 (16.67%) | 3 (25%) | |
M protein subtype, n (%) | |||
IgG kappa | 1 (8.33) | ||
IgG lamda | 2 (16.67%) | ||
IgA kappa | 3 (25%) | ||
IgA lamda | 2 (16.67%) | ||
Kappa light chain | 2 (16.67%) | ||
Lamda light chain | 2 (16.67%) | ||
Median plasma cells in bone marrow (%), (range) | 20 (0.5–58) | 2 (0–11) | 0.002 |
